SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for CEL SCI CORP (CVM) (CIK 0000725363) (CVM) — Apr 15, 2020

CEL SCI CORP (CVM) (CIK 0000725363)
Date: April 15, 2020 · CIK: 0000725363 · Accession: 0000000000-20-003256

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237623

Date
April 15, 2020
Author
Geert Kersten
Form
UPLOAD
Company
CEL SCI CORP (CVM) (CIK 0000725363)

Letter

April 15, 2020 Geert Kersten Chief Executive Officer CEL-SCI Corporation 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 Re:CEL-SCI Corporation Registration Statement on Form S-1 Filed April 9, 2020 File No. 333-237623 Dear Mr. Kersten: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William T. Hart, Esq.

Show Raw Text
April 15, 2020
Geert Kersten
Chief Executive Officer
CEL-SCI Corporation
8229 Boone Blvd., Suite 802
Vienna, Virginia 22182
Re:CEL-SCI Corporation
Registration Statement on Form S-1
Filed April 9, 2020
File No. 333-237623
Dear Mr. Kersten:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       William T. Hart, Esq.